CN111945415B - Drug-loaded thermochromic hydrogel functionalized fabric and preparation and application thereof - Google Patents
Drug-loaded thermochromic hydrogel functionalized fabric and preparation and application thereof Download PDFInfo
- Publication number
- CN111945415B CN111945415B CN202010662148.7A CN202010662148A CN111945415B CN 111945415 B CN111945415 B CN 111945415B CN 202010662148 A CN202010662148 A CN 202010662148A CN 111945415 B CN111945415 B CN 111945415B
- Authority
- CN
- China
- Prior art keywords
- fabric
- drug
- nipam
- aac
- loaded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 96
- 229940079593 drug Drugs 0.000 title claims abstract description 75
- 239000004744 fabric Substances 0.000 title claims abstract description 68
- 239000000017 hydrogel Substances 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 title abstract description 4
- 239000006249 magnetic particle Substances 0.000 claims abstract description 24
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 17
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims abstract description 16
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 16
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000000178 monomer Substances 0.000 claims abstract description 13
- 239000006185 dispersion Substances 0.000 claims abstract description 12
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims abstract description 8
- 229920000642 polymer Polymers 0.000 claims abstract description 7
- 238000010521 absorption reaction Methods 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims abstract description 6
- 239000002904 solvent Substances 0.000 claims abstract description 5
- 238000005406 washing Methods 0.000 claims abstract description 5
- 238000006116 polymerization reaction Methods 0.000 claims abstract description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 44
- 239000000243 solution Substances 0.000 claims description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 14
- 238000012544 monitoring process Methods 0.000 claims description 12
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 claims description 8
- 229920000728 polyester Polymers 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 238000009832 plasma treatment Methods 0.000 claims description 7
- 239000011259 mixed solution Substances 0.000 claims description 6
- 230000000007 visual effect Effects 0.000 claims description 5
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 238000013267 controlled drug release Methods 0.000 claims description 3
- 239000000011 acetone peroxide Substances 0.000 claims description 2
- 238000001027 hydrothermal synthesis Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 abstract description 6
- 238000001132 ultrasonic dispersion Methods 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 description 12
- 238000011068 loading method Methods 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 238000012377 drug delivery Methods 0.000 description 9
- 239000011521 glass Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 229920000858 Cyclodextrin Polymers 0.000 description 6
- 239000001116 FEMA 4028 Substances 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 6
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 6
- 229960004853 betadex Drugs 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 230000008021 deposition Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000011229 interlayer Substances 0.000 description 6
- 238000009210 therapy by ultrasound Methods 0.000 description 6
- 239000013078 crystal Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 239000004753 textile Substances 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229910021642 ultra pure water Inorganic materials 0.000 description 4
- 239000012498 ultrapure water Substances 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003999 initiator Substances 0.000 description 3
- IDIIJJHBXUESQI-DFIJPDEKSA-N moxifloxacin hydrochloride Chemical compound Cl.COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 IDIIJJHBXUESQI-DFIJPDEKSA-N 0.000 description 3
- 230000036457 multidrug resistance Effects 0.000 description 3
- 230000000379 polymerizing effect Effects 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229960005112 moxifloxacin hydrochloride Drugs 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 239000004038 photonic crystal Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- JWYVGKFDLWWQJX-UHFFFAOYSA-N 1-ethenylazepan-2-one Chemical compound C=CN1CCCCCC1=O JWYVGKFDLWWQJX-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZPHHRHKVOJNRNI-UHFFFAOYSA-N N-(hydroxymethyl)prop-2-enamide N-propan-2-ylprop-2-enamide Chemical compound C(C=C)(=O)NCO.C(C=C)(=O)NC(C)C ZPHHRHKVOJNRNI-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000000985 reflectance spectrum Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229920000208 temperature-responsive polymer Polymers 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Images
Classifications
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M10/00—Physical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. ultrasonic, corona discharge, irradiation, electric currents, or magnetic fields; Physical treatment combined with treatment with chemical compounds or elements
- D06M10/02—Physical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. ultrasonic, corona discharge, irradiation, electric currents, or magnetic fields; Physical treatment combined with treatment with chemical compounds or elements ultrasonic or sonic; Corona discharge
- D06M10/025—Corona discharge or low temperature plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M11/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising
- D06M11/32—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising with oxygen, ozone, ozonides, oxides, hydroxides or percompounds; Salts derived from anions with an amphoteric element-oxygen bond
- D06M11/36—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising with oxygen, ozone, ozonides, oxides, hydroxides or percompounds; Salts derived from anions with an amphoteric element-oxygen bond with oxides, hydroxides or mixed oxides; with salts derived from anions with an amphoteric element-oxygen bond
- D06M11/49—Oxides or hydroxides of elements of Groups 8, 9,10 or 18 of the Periodic Table; Ferrates; Cobaltates; Nickelates; Ruthenates; Osmates; Rhodates; Iridates; Palladates; Platinates
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M11/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising
- D06M11/73—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof
- D06M11/74—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with carbon or graphite; with carbides; with graphitic acids or their salts
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M15/00—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment
- D06M15/01—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment with natural macromolecular compounds or derivatives thereof
- D06M15/03—Polysaccharides or derivatives thereof
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M15/00—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment
- D06M15/19—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment with synthetic macromolecular compounds
- D06M15/21—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
- D06M15/263—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds of unsaturated carboxylic acids; Salts or esters thereof
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M15/00—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment
- D06M15/19—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment with synthetic macromolecular compounds
- D06M15/21—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
- D06M15/285—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds of unsaturated carboxylic acid amides or imides
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M2101/00—Chemical constitution of the fibres, threads, yarns, fabrics or fibrous goods made from such materials, to be treated
- D06M2101/16—Synthetic fibres, other than mineral fibres
- D06M2101/30—Synthetic polymers consisting of macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- D06M2101/32—Polyesters
Landscapes
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Textile Engineering (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plasma & Fusion (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a drug-loaded thermochromic hydrogel functionalized fabric and preparation and application thereof. The surface of the fabric is loaded with doped Fe3O4@ C thermally responsive polymer P (NIPAM-AAc) of magnetic particles and a drug. The method comprises the following steps: monomer N-isopropyl acrylamide NIPAM, acrylic acid AAc, cross-linking agent and photoinitiator are ultrasonically dispersed in solvent, and Fe is added3O4The @ C magnetic particle dispersion liquid is subjected to ultrasonic dispersion, the obtained mixed liquid is coated on the surface of a fabric, ultraviolet polymerization is carried out under a magnetic field, washing is carried out, and the fabric is placed in a drug solution for drug absorption. The method is simple, convenient and practical, the prepared fabric does not need other equipment to provide energy for the fabric, the fabric can be recycled, and the fabric is an environment-friendly material, has good tensile property and cannot be easily broken or fall off in the using process.
Description
Technical Field
The invention belongs to the field of intelligent in-vitro drug release materials and preparation and application thereof, and particularly relates to a drug-loaded thermochromic hydrogel functionalized fabric and a preparation method and application thereof.
Background
In vitro drug delivery systems, such as transdermal and wound delivery, are of great interest due to the unique properties of sustained delivery of therapeutic agents. They have many advantages over traditional oral, nasal, intramuscular and intravenous administration, such as prevention of drug degradation in the gastrointestinal tract, first pass effects of the drug, drug hepatotoxicity, pain from injection, and the risk of disease transmission with repeated needle use. In vitro drug delivery systems are a non-invasive, painless treatment and skin is the largest organ of the human body, and extensive exposure of the skin facilitates absorption of therapeutic compounds that are not readily administered orally or nasally, thereby improving the bioavailability of certain drugs. In vitro drug delivery systems can be divided into passive (sustained release) and active (on-demand) drug delivery systems, with sustained release limited to a monotonic curve of drug release, which, regardless of the patient's specific needs during the course of treatment, can lead to multidrug resistance and increased toxicity to healthy cells, resulting in decreased therapeutic efficacy. Unlike sustained release, on-demand release can be initiated or suspended by the use of specific external stimuli (e.g., temperature, ultrasound, and low voltage current). This can effectively prevent serious side effects caused by an excess of the drug and poor therapeutic effects caused by a small dose of the drug.
However, an ideal in vitro drug delivery system should be able to control drug delivery in terms of dose, duration and location, and to do so, effective means of monitoring drug content in real time is essential, and monitoring the drug can guide appropriate drug dosage, improve treatment efficiency, prevent multidrug resistance, and the like. At present, the strategy for monitoring the content of the drug in vitro mainly utilizes the covalent binding of fluorescent agent and drug molecules and utilizes near infrared fluorescence imaging to monitor the drug molecules in real time.
In the literature (Materials Science and Engineering C,2016,62,113), a thermally triggered transdermal drug delivery system is designed by using a thermally responsive polymer poly (N-vinyl caprolactam) (PNVCL), and the application of the epidermal controlled drug release is explored through the load of acetaminophen, however, due to the lack of an effective drug monitoring means, the drug dosage cannot be effectively guided, and a signal for reminding replacement in time after the drug release is finished is lacked, so that the application value is greatly limited.
Disclosure of Invention
The invention aims to solve the technical problem of providing a drug-loaded thermochromic hydrogel functionalized fabric and preparation and application thereof, so as to overcome the defects that expensive equipment is required for in vitro monitoring of drug content in the prior art and the like. The invention monitors the drug release condition by naked eyes with colors.
The invention provides a drug-loaded thermochromic hydrogel functionalized fabric, wherein Fe is loaded and doped on the surface of the fabric3O4@ C thermally responsive polymer P (NIPAM-AAc) of magnetic particles and a drug.
The structural formula of the thermal response type polymer P (NIPAM-AAc) is as follows:
the invention also provides a preparation method of the drug-loaded thermochromic hydrogel functionalized fabric, which comprises the following steps:
monomer N-isopropyl acrylamide NIPAM, acrylic acid AAc, cross-linking agent and photoinitiator are ultrasonically dispersed in solvent, and Fe is added3O4@ C magnetic particle dispersion liquid, ultrasonic dispersion, coating the obtained mixed liquid on the surface of the fabric,carrying out ultraviolet polymerization in a magnetic field, washing, placing in a medicinal solution for absorbing medicine to obtain the medicine-carrying thermochromic hydrogel functionalized fabric, wherein the mass ratio of NIPAM to AAc is 5: 1-20: 1, mixed solution of NIPAM and AAc and Fe3O4The volume ratio of the @ C magnetic particle dispersion liquid is 2: 1-4: 1.
Said Fe3O4The preparation method of the @ C dispersion comprises the following steps: dissolving ferrocene in acetone, dropwise adding 30% hydrogen peroxide while stirring, carrying out hydrothermal reaction at 180-200 ℃ for 48-72 h to obtain Fe3O4And (3) dispersing the @ C magnetic particles in ethylene glycol to obtain the material, wherein the proportion of ferrocene, acetone and hydrogen peroxide is 0.3-0.5 g: 50-60 ml: 1 to 3ml of Fe3O4The concentration of the @ C dispersion is 20-40 mg/ml.
Said Fe3O4The particle size of the @ C magnetic particles is 180-330 nm.
The cross-linking agent is BIS, and the dosage of the BIS is 1-2% of the total mass of NIPAM and AAc monomers.
The photoinitiator is HMPP, and the using amount of the HMPP is 0.5-1% of the total mass of NIPAM and AAc monomers.
The solvent is a mixed solution of ethanol and glycol, and the volume ratio of the ethanol to the glycol is 1: 1.
The total concentration of the NIPAM and AAc monomers is 0.7-0.8 g/ml.
The ratio of the volume of the mixed solution to the surface area of the fabric is 0.05ml/cm2~0.15ml/cm2。
The fabric is a black polyester fabric.
And carrying out oxygen plasma treatment on the surface of the fabric, wherein the parameters of the oxygen plasma treatment are 100-300W and 30-90 s.
The magnetic field intensity is 0.2-0.5T.
The concentration of the medicine is 0.1-5 mg/ml.
The washing is as follows: the unreacted monomer was removed by washing with ultrapure water.
The drug solution is a beta-CD-Mox clathrate PBS solution.
The medicine is placed in the medicine solution for sucking for 2 hours at room temperature.
The invention also provides application of the drug-loaded thermochromic hydrogel functionalized fabric in controlled drug release and visual real-time monitoring of drug content.
The invention utilizes NIPAM, AAc and Fe3O4@ C as raw material, by mixing Fe3O4The PCs structure of the @ C magnetic particles is introduced into a thermal response type polymer P (NIPAM-AAc), so that synchronous on-demand release of the medicine and visual real-time monitoring of the medicine content are realized, and the introduction of the hydrophilic AAc enables the phase transition temperature (LCST) of PNIAPM to be increased to 40 ℃ which is higher than the body surface temperature, so that the medicine can be stored in the P (NIPAM-AAc) at room temperature and released by mild external heating. Furthermore, the presence of a textile matrix is effective in preventing the hydrogel from breaking and falling off when overstretched, and finally, based on Fe3O4The lattice spacing of the @ C magnetic particles PCs changes with the absorption or release of the drug, i.e., the color changes. The synchronization of these thermo-responsive color changes and drug absorption/release behavior provides an effective means for visualization and real-time monitoring of drug content.
Advantageous effects
(1) The invention is simple and practical, and realizes the synchronous on-demand release of the medicine and the visual real-time monitoring of the medicine content through the swelling and deswelling behaviors of the thermal response type polymer P (NIPAM-AAc) and the color change based on the PCs structure. The invention provides a convenient, convenient and effective visual real-time medicine monitoring means without external equipment.
(2) The thermochromic hydrogel functional fabric prepared by the invention does not need other equipment to provide energy for the thermochromic hydrogel functional fabric, does not cause pollution, and is an environment-friendly material.
(3) The thermochromic hydrogel functionalized fabric prepared by the invention has good tensile property, cannot be easily broken and fall off in the use process, and the color is kept stable after each stretching recovery.
Drawings
FIG. 1 is a cross-sectional SEM image of a drug-loaded lyophilized P (NIPAM-AAc) hydrogel of example 3; wherein a is a low-power section SEM picture; b is a high-power cross section SEM picture, wherein the crystal is beta-CD/Mox inclusion compound.
FIG. 2 is a representation of the Fe-based content of the P (NIPAM-AAc) hydrogel of example 33O4Section SEM image of one-dimensional chain photonic crystal structure of @ C magnetic particle.
Fig. 3 is a relationship between the color of the thermochromic hydrogel functionalized fabric prepared in example 3 and the cumulative drug loading/release rate and a digital photograph thereof. Wherein (a, b) is a relation graph of the color of the thermochromic hydrogel functionalized fabric and the cumulative drug loading rate; (c, d) is a relation graph of the color of the thermochromic hydrogel functionalized fabric and the cumulative release rate of the drug; (e) is a digital photo of the color change of the thermochromic hydrogel functionalized fabric in the drug loading/releasing process.
Fig. 4 is a tensile stability test of the thermochromic hydrogel functionalized fabric prepared in example 3. Wherein a is a reflected spectrogram obtained after 30 times of stretching and 5 times of recovery; b is an optical photograph of the stretching process.
Fig. 5 shows in vitro antibacterial experiments and animal experiments of the drug-loaded thermochromic hydrogel functionalized fabric prepared in example 3. Wherein (a) is an in vitro antibacterial experiment; and (b) and (c) are digital photos of mouse body surface wound healing of the drug-loaded thermochromic hydrogel functional fabric and statistical data thereof.
Detailed Description
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Further, it should be understood that various changes or modifications of the present invention may be made by those skilled in the art after reading the teaching of the present invention, and such equivalents may fall within the scope of the present invention as defined in the appended claims.
Acrylic acid (AAc), absolute ethanol, and ethylene glycol are available from the pharmaceutical industry group chemical company. Ferrocene, N-isopropylacrylamide (NIPAM), N' -methylenebisacrylamide (BIS), photoinitiator 1173(HMPP), Phosphate Buffered Saline (PBS) was purchased from alatin reagent (shanghai) ltd. beta-Cyclodextrin (beta-CD), moxifloxacin hydrochloride (Mox) was purchased from Sigma Aldrich (Shanghai) trade company, Inc. Prior to use, the NIPAM was recrystallized to further purify the inhibitor.
The tensile property of the thermochromic hydrogel functionalized fabric is measured by a micro-control electronic universal tester (20KN/WDW3020), the color change property is measured by a fiber optic spectrometer (G2000-Pro-Ex), and the drug absorption and release amount is measured by an ultraviolet spectrophotometer (UV 3600).
Drug loading procedure relies on swelling of P (NIPAM-AAc) hydrogel at room temperature (25 ℃), placing the P (NIPAM-AAc) hydrogel functionalized textile in a beta-CD-Mox solution in PBS and measuring the absorbance of the free drug at 280nm at intervals. The concentration of the free drug solution was obtained from the absorbance-concentration standard curve of β -CD-Mox and compared to the original drug solution (mass ratio determined as drug loading). The reflectance spectra of P (NIPAM-AAc) hydrogel functionalized textiles were measured at each time point and the color versus drug loading was determined by curve fitting. The measurement procedure for the drug release process is substantially identical to that described above.
In the antibacterial experiment, the hydrogel functionalized textile is firstly cut into small pieces (1X1 cm)2) And immersed in bacterial suspensions (each containing 500. mu.l of Staphylococcus aureus suspension in a 24-well plate) and incubated at a temperature and for a time sufficient to obtain 104The double diluted bacterial solution was spread evenly on fresh agar plates and placed in an incubator at 37 ℃ for 24 hours. The formed bacterial colonies were then observed and the number of Staphylococcus aureus was estimated by Colony Forming Unit (CFU) counting.
In the biological experiment, the mice are divided into 6 groups, and each group comprises 5 mice. The mouse's dorsal hair was scraped off, washed with alcohol, and the mouse's epidermis was cut 7X 7mm with a scalpel2Of the wound is circular. After s.aureus infection, the hydrogel functionalized textile was applied to the wound area and the drug was released on days 1, 2 and 3 as needed. A commercially available wound dressing was used as a blank control, and free drug was added under the same conditions as a positive control, and a drug-loaded hydrogel functionalized fabric was used as an experimental group (where the absorbed drug concentrations were divided into 100 μ g/ml,1mg/ml and 5 mg/ml). Photographs of the wound area were taken after days 3, 7 and 14 and determined by Image jWound area size at each time point. And calculating the rate of healing of the wound by the following formula:
wherein A is0And AtWound area at time 0 and time t, respectively.
Example 1
Adding 0.3g of ferrocene into 60ml of acetone, dissolving by ultrasonic treatment for 5 minutes, then dropwise adding 1ml of 30% hydrogen peroxide, stirring for 2 hours, uniformly stirring, transferring into a 100ml hydrothermal kettle, reacting at 180 ℃ for 48 hours, taking out and cooling to room temperature. Performing magnetic deposition on the obtained product with a magnet with the magnetic field intensity of 0.2T, dissolving again with acetone, and continuing the magnetic deposition for 3 times. Fe obtained3O4@ C magnetic particles (180nm) were redispersed in ethylene glycol (21 mg/ml). Then 2g NIPAM, 100. mu.l AAc, 20mg BIS were added to 3ml ethanol/ethylene glycol (1: 1) and sonicated to complete dissolution, then 11. mu.L HMPP and finally 200. mu.L Fe3O4@ C magnetic particle ethylene glycol dispersion (20mg/ml) was added to the above prepolymer solution (600. mu.L), and ultrasonically mixed for 10 min. Then, the polyester fabric (6 x 2cm) was subjected to oxygen plasma treatment to make the surface hydrophilic (parameters set to 300W, 1min), and then the treated polyester fabric was placed in the interlayer of two glass plates, and Fe was injected by a syringe3O4Injecting a @ C magnetic particle doped P (NIPAM-AAc) prepolymer solution into the interlayer, placing a glass plate above a magnet (0.2T), polymerizing for 2min by adopting ultraviolet light (356nm), removing the glass plate to prepare a P (NIPAM-AAc) hydrogel functionalized fabric with a structural color, and swelling the fabric for three times by using PBS to remove unreacted monomers, an initiator and a crosslinking agent. Immersing the P (NIPAM-AAc) hydrogel functionalized fabric into a beta-CD-Mox clathrate compound (beta-CD and Mox are added into ultrapure water according to a molar ratio of 1:1, performing ultrasonic treatment at 60 ℃ for 24 hours, cooling to room temperature to precipitate beta-CD-Mox clathrate compound crystal) PBS solution (2mg/ml), fully sucking the medicine at room temperature (25 ℃) for 2 hours, and finally removing the residual solution on the surface to obtain the thermochromic hydrogel functionalized fabric with medicine loading.
Example 2
Adding 0.4g of ferrocene into 60ml of acetone, dissolving by ultrasonic treatment for 5 minutes, then dropwise adding 2ml of 30% hydrogen peroxide, stirring for 2 hours, uniformly stirring, transferring into a 100ml hydrothermal kettle, reacting at 190 ℃ for 64 hours, taking out and cooling to room temperature. Performing magnetic deposition on the obtained product with a magnet with the magnetic field intensity of 0.3T, dissolving again with acetone, and continuing the magnetic deposition for 3 times. Fe obtained3O4@ C magnetic particles (240nm) were redispersed in ethylene glycol (30 mg/ml). Then 2g NIPAM, 200. mu.l AAc, 30mg BIS were added to 3ml ethanol/ethylene glycol (1: 1) and sonicated to complete dissolution, then 15. mu.L HMPP and finally 300. mu.L Fe3O4@ C magnetic particle ethylene glycol dispersion (30mg/ml) was added to the above prepolymer solution (900. mu.L), and ultrasonically mixed for 10 min. Then, the polyester fabric (6 x 2cm) was subjected to oxygen plasma treatment to make the surface hydrophilic (parameters set to 300W, 1min), and then the treated polyester fabric was placed in the interlayer of two glass plates, and Fe was injected by a syringe3O4Injecting a @ C magnetic particle doped P (NIPAM-AAc) prepolymer solution into the interlayer, placing a glass plate above a magnet (0.3T), polymerizing for 2min by adopting ultraviolet light (356nm), removing the glass plate to prepare a P (NIPAM-AAc) hydrogel functionalized fabric with a structural color, and swelling the fabric for three times by using PBS to remove unreacted monomers, an initiator and a crosslinking agent. Immersing the P (NIPAM-AAc) hydrogel functionalized fabric into a beta-CD-Mox clathrate compound (beta-CD and Mox are added into ultrapure water according to a molar ratio of 1:1, performing ultrasonic treatment at 60 ℃ for 24 hours, cooling to room temperature to precipitate beta-CD-Mox clathrate compound crystal) PBS solution (3mg/ml), fully sucking the medicine at room temperature (25 ℃) for 2 hours, and finally removing the residual solution on the surface to obtain the thermochromic hydrogel functionalized fabric with medicine loading.
Example 3
Adding 0.5g of ferrocene into 60ml of acetone, dissolving by ultrasonic treatment for 5 minutes, then dropwise adding 2ml of 30% hydrogen peroxide, stirring for 2 hours, uniformly stirring, transferring into a 100ml hydrothermal kettle, reacting at 200 ℃ for 72 hours, taking out and cooling to room temperature. Performing magnetic deposition on the obtained product with a magnet with the magnetic field intensity of 0.4T, dissolving again with acetone, and continuing the magnetic deposition for 3 times. Fe obtained3O4@ C magnetic particles (300nm) redispersed in ethylene glycol (40mg/ml). Then 2g NIPAM, 400. mu.l AAc, 40mg BIS in 3ml ethanol/ethylene glycol (1: 1) and sonicated to dissolve completely, then 20. mu.L HMPP and finally 400. mu.L Fe3O4@ C magnetic particle ethylene glycol dispersion (40mg/ml) was added to the prepolymer solution (1200. mu.L), and ultrasonically mixed for 10 min. Then, the polyester fabric (6 x 2cm) was subjected to oxygen plasma treatment to make the surface hydrophilic (parameters set to 300W, 1min), and then the treated polyester fabric was placed in the interlayer of two glass plates, and Fe was injected by a syringe3O4Injecting a @ C magnetic particle doped P (NIPAM-AAc) prepolymer solution into the interlayer, placing a glass plate above a magnet (0.4T), polymerizing for 2min by adopting ultraviolet light (356nm), removing the glass plate to prepare a P (NIPAM-AAc) hydrogel functionalized fabric with a structural color, and swelling the fabric for three times by using PBS to remove unreacted monomers, an initiator and a crosslinking agent. Immersing the P (NIPAM-AAc) hydrogel functionalized fabric into a beta-CD-Mox clathrate compound (beta-CD and Mox are added into ultrapure water according to a molar ratio of 1:1, performing ultrasonic treatment at 60 ℃ for 24 hours, cooling to room temperature to precipitate beta-CD-Mox clathrate compound crystal) PBS solution (5mg/ml), fully sucking the medicine at room temperature (25 ℃) for 2 hours, and finally removing the residual solution on the surface to obtain the thermochromic hydrogel functionalized fabric with medicine loading.
FIG. 1 shows that: the P (NIPAM-AAc) gel has a porous structure, so that the drug can be conveniently loaded and released, wherein the drug crystals are arranged in the inner holes of the freeze-dried gel, and the fact that the drug can be successfully loaded into the P (NIPAM-AAc) gel is shown.
FIG. 2 shows that: fe3O4The @ C magnetic particles are assembled into a one-dimensional chain photonic crystal structure in the P (NIPAM-AAc) gel, so that the gel presents bright color.
FIG. 3 shows: the color of the P (NIPAM-AAc) hydrogel functionalized fabric and the drug loading/release amount show approximate linear relation, and (e) the figure digital photograph shows that the color of the P (NIPAM-AAc) hydrogel functionalized fabric changes from blue to orange-red along with the drug loading process; and the color changed from orange-red to blue as the drug was released. And at each drug content time point corresponds to a different color between blue and orange-red.
FIG. 4 shows that: the P (NIPAM-AAc) hydrogel functionalized fabric still has no obvious fracture or shedding after being curled and stretched (30%) for 30 times, and the reflection spectrum after being stretched and recovered by 1, 5, 10, 15, 20, 25 and 30 times has no obvious change of peak position and intensity.
FIG. 5 shows that: FIG. 5(a) shows that the drug-loaded P (NIPAM-AAc) hydrogel functionalized fabric has a specific warm drug release function, the strain still exists after 6h incubation at 30 ℃ and the strain basically disappears at 40 ℃, which shows that the drug can be stored in the gel at body surface temperature (30 ℃) and release is triggered under mild thermal stimulation (40 ℃). FIG. 5(b, c) mouse epidermal wound healing experiment shows that the P (NIPAM-AAc) hydrogel functionalized fabric has the functions of antibiosis and wound healing promotion.
Comparative example 1
Compared with the in vitro drug delivery system in the embodiment 3 of the present invention, the functionalized fabric in the embodiment 3 can realize the mild thermal stimulation triggered drug release on demand, and can monitor the drug content in real time through color visualization, so that the system has important significance for guiding the drug dosage and avoiding multi-drug resistance.
Comparative example 2
In the literature (Advanced Functional Materials,2019, 497, 1902127), a non-woven fabric based on the thermo-responsive polymer poly (N-isopropylacrylamide-N-methylolacrylamide) (P (NIPAM-HMAAm)) was prepared by electrospinning method design and loaded with the antibiotic moxifloxacin hydrochloride by immersion. The obtained non-woven fabric is compounded with the heating coil to realize the release of the electrically stimulated drug according to the requirement. Compared with the in-vitro drug delivery system in the embodiment 3 of the invention, the in-vitro drug delivery system in the embodiment 3 not only has the controlled release performance of the drug as required, but also has the function of visually monitoring the content of the drug in real time, can provide a definite guide for the dosage of the drug, and avoids the side effect caused by excessive drug administration.
Claims (9)
1. The drug-loaded thermochromic hydrogel functionalized fabric is characterized in that Fe is loaded and doped on the surface of the fabric3O4The thermal response type polymer P (NIPAM-AAc) of the @ C magnetic particles and the medicine have the structural formula:
2. a preparation method of a drug-loaded thermochromic hydrogel functionalized fabric comprises the following steps:
monomer N-isopropyl acrylamide NIPAM, acrylic acid AAc, cross-linking agent and photoinitiator are ultrasonically dispersed in solvent, and Fe is added3O4The @ C magnetic particle dispersion liquid is ultrasonically dispersed, the obtained mixed liquid is coated on the surface of a fabric, ultraviolet polymerization and washing are carried out under a magnetic field, medicine absorption is carried out in the medicine solution, the medicine-carrying thermochromic hydrogel functionalized fabric is obtained, and the mass ratio of NIPAM to AAc is 5: 1-20: 1, mixed solution of NIPAM and AAc and Fe3O4The volume ratio of the @ C magnetic particle dispersion liquid is 2: 1-4: 1.
3. The method of claim 2, wherein the Fe3O4The preparation method of the @ C dispersion comprises the following steps: dissolving ferrocene in acetone, dropwise adding hydrogen peroxide while stirring, carrying out hydrothermal reaction at 180-200 ℃ for 48-72 h, and obtaining Fe3O4And (3) dispersing the @ C magnetic particles in ethylene glycol to obtain the material, wherein the proportion of ferrocene, acetone and hydrogen peroxide is 0.3-0.5 g: 50-60 ml: 1 to 3ml of Fe3O4The concentration of the @ C dispersion is 20-40 mg/ml.
4. The method according to claim 2, wherein the cross-linking agent is BIS, and the amount of BIS is 1-2% of the total mass of NIPAM and AAc monomers; the photoinitiator is HMPP, and the using amount of the HMPP is 0.5-1% of the total mass of NIPAM and AAc monomers.
5. The method according to claim 2, wherein the solvent is a mixed solution of ethanol and glycol, and the volume ratio of the ethanol to the glycol is 1: 1; the total concentration of NIPAM and AAc monomers is 0.7-0.8 g/ml.
6. The method of claim 2, wherein the volume to fabric surface area ratio of the mixed solution is 0.05ml/cm2~0.15ml/cm2。
7. The method of claim 2, wherein the fabric is a black polyester fabric; and performing oxygen plasma treatment on the surface of the fabric, wherein the parameters of the oxygen plasma treatment are 100-300W and 30-90 s.
8. The method according to claim 2, wherein the magnetic field strength is 0.2-0.5T; the concentration of the medicine is 0.1-5 mg/ml.
9. Use of the fabric of claim 1 for controlled drug release and visual real-time monitoring of drug content.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010662148.7A CN111945415B (en) | 2020-07-10 | 2020-07-10 | Drug-loaded thermochromic hydrogel functionalized fabric and preparation and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010662148.7A CN111945415B (en) | 2020-07-10 | 2020-07-10 | Drug-loaded thermochromic hydrogel functionalized fabric and preparation and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111945415A CN111945415A (en) | 2020-11-17 |
CN111945415B true CN111945415B (en) | 2021-10-26 |
Family
ID=73341760
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010662148.7A Active CN111945415B (en) | 2020-07-10 | 2020-07-10 | Drug-loaded thermochromic hydrogel functionalized fabric and preparation and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111945415B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113150322B (en) * | 2021-04-12 | 2022-11-18 | 大连理工大学 | Preparation method of semi-invasive brain-computer interface flexible electrode material with magnetic control effect |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001254273A (en) * | 2000-03-10 | 2001-09-21 | Toray Ind Inc | Finishing agent for fiber, fiber structure by using the same and method for producing the same |
TW201247225A (en) * | 2011-05-17 | 2012-12-01 | Univ Nat Chiao Tung | Drug carrier with thermal sensitivity, manufacturing method thereof, and use of the same as NMR contrast agent |
CN104264445A (en) * | 2014-09-09 | 2015-01-07 | 东华大学 | Method for preparing schemochrome carbon fiber based on P(NIPAAm-co-AAc) nanosphere |
CN104382883A (en) * | 2014-08-28 | 2015-03-04 | 东华大学 | Preparation method for nanometer drug-loaded fiber membrane with temperature-sensitive drug release performance |
CN104843800A (en) * | 2015-03-25 | 2015-08-19 | 东莞市迈科科技有限公司 | Solvothermal preparation method for carbon-coated ferriferrous oxide negative electrode material |
CN106223026A (en) * | 2016-07-26 | 2016-12-14 | 天津工业大学 | A kind of preparation method of quick high Absorbent Nonwovens |
CN107881649A (en) * | 2016-09-29 | 2018-04-06 | 南京林业大学 | A kind of preparation method of the nanofiber water-oil separationg film of photothermal response |
CN109322155A (en) * | 2018-09-14 | 2019-02-12 | 晋江瑞碧科技有限公司 | A kind of preparation method of triple responsive nano fiber hydrogels |
-
2020
- 2020-07-10 CN CN202010662148.7A patent/CN111945415B/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001254273A (en) * | 2000-03-10 | 2001-09-21 | Toray Ind Inc | Finishing agent for fiber, fiber structure by using the same and method for producing the same |
TW201247225A (en) * | 2011-05-17 | 2012-12-01 | Univ Nat Chiao Tung | Drug carrier with thermal sensitivity, manufacturing method thereof, and use of the same as NMR contrast agent |
CN104382883A (en) * | 2014-08-28 | 2015-03-04 | 东华大学 | Preparation method for nanometer drug-loaded fiber membrane with temperature-sensitive drug release performance |
CN104264445A (en) * | 2014-09-09 | 2015-01-07 | 东华大学 | Method for preparing schemochrome carbon fiber based on P(NIPAAm-co-AAc) nanosphere |
CN104843800A (en) * | 2015-03-25 | 2015-08-19 | 东莞市迈科科技有限公司 | Solvothermal preparation method for carbon-coated ferriferrous oxide negative electrode material |
CN106223026A (en) * | 2016-07-26 | 2016-12-14 | 天津工业大学 | A kind of preparation method of quick high Absorbent Nonwovens |
CN107881649A (en) * | 2016-09-29 | 2018-04-06 | 南京林业大学 | A kind of preparation method of the nanofiber water-oil separationg film of photothermal response |
CN109322155A (en) * | 2018-09-14 | 2019-02-12 | 晋江瑞碧科技有限公司 | A kind of preparation method of triple responsive nano fiber hydrogels |
Non-Patent Citations (2)
Title |
---|
Acid and temperature dual-responsive cotton fabrics with polymer coating;Junteng Chen et al.;《Composites Communications》;20170406(第4期);第399–407页 * |
Highly sensitive multiresponsive photonic hydrogels based on acrosslinked Acrylamide-N-isopropylacrylamide (AM-NIPAM) co-polymer containing Fe3O4@C crystalline colloidal arrays;Xiaobing Tang et al.;《Sensors and Actuators B》;20160602(第236期);第10–15页 * |
Also Published As
Publication number | Publication date |
---|---|
CN111945415A (en) | 2020-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | Ultrasound-triggered piezocatalytic composite hydrogels for promoting bacterial-infected wound healing | |
Gong et al. | Thermochromic hydrogel-functionalized textiles for synchronous visual monitoring of on-demand in vitro drug release | |
CN111945415B (en) | Drug-loaded thermochromic hydrogel functionalized fabric and preparation and application thereof | |
EP0626974A1 (en) | Mitogen-free substance, its preparation and its use. | |
DE1617393A1 (en) | Carrier for biologically active substances | |
Barczikai et al. | Interaction of silver nanoparticle and commonly used anti-inflammatory drug within a poly (amino acid) derivative fibrous mesh | |
Hoseinpour Najar et al. | Preparation and in vivo evaluation of a novel gel-based wound dressing using arginine–alginate surface-modified chitosan nanofibers | |
Qiu et al. | ICG-loaded photodynamic chitosan/polyvinyl alcohol composite nanofibers: Anti-resistant bacterial effect and improved healing of infected wounds | |
US20090285885A1 (en) | Method of forming a drug nanocarrier having a magnetic shell | |
CN111481737A (en) | Magnetic temperature-sensitive hydrogel for near-infrared light-controlled release of nitric oxide, and preparation and application thereof | |
Cao et al. | Cerium oxide nanoparticle-loaded polyvinyl alcohol nanogels delivery for wound healing care systems on surgery | |
CN107474160A (en) | A kind of Phosphorylcholine base polyethylene glycol-chitosan and preparation method thereof | |
Adamu et al. | Self‐Responsive Electrospun Nanofibers Wound Dressings: The Future of Wound Care | |
Li et al. | Dissolving microneedles based on ZnO nanoparticles and an ionic liquid as synergistic antibacterial agents | |
Lai et al. | Oxygen-producing composite dressing activated by photothermal and piezoelectric effects for accelerated healing of infected wounds | |
KR102476844B1 (en) | Wound treatment and dressing material containing Prussian blue nanoparticles, and manufacturing method thereof | |
CN110559453B (en) | Magnetic nano-particles for imaging guidance and preparation method thereof | |
Yi et al. | Gold nanoclusters encapsulated microneedle patches with antibacterial and self‐monitoring capacities for wound management | |
Li et al. | The construct of triple responsive nanocomposite and its antibacterial effect | |
CN114832152B (en) | Photothermal antibacterial medical injectable hydrogel and preparation method thereof | |
CN109395080A (en) | A kind of multi-functional albumen gel and preparation method thereof | |
Luo et al. | Drug cross‐linking electrospun fiber for effective infected wound healing | |
CN114191379A (en) | Medicine for repairing skin injury by using Pluronic F127 as carrier to perform local transgenosis in vivo and preparation method | |
Li et al. | A drug-laden elastomer for surgical treatment of anal fistula | |
KR100835898B1 (en) | Poly vinyl alcohol hydrogel particle by using acid hydrolysis and method the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |